|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM117747866 |
| 003 |
DE-627 |
| 005 |
20231222181217.0 |
| 007 |
tu |
| 008 |
231222s2002 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0393.xml
|
| 035 |
|
|
|a (DE-627)NLM117747866
|
| 035 |
|
|
|a (NLM)11890708
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Robles, David T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Millennium award recipient contribution. Identification of children with early onset and high incidence of anti-islet autoantibodies
|
| 264 |
|
1 |
|c 2002
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.04.2002
|
| 500 |
|
|
|a Date Revised 17.11.2011
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A total of 21,000 general population newborns (NECs) and 693 young siblings-offspring of patients with type 1A diabetes (SOCs) were class II genotyped and 293 NECs and 72 SOCs with the high-risk genotype, DR3/4, DQB1*0302 have been prospectively evaluated. Seventeen individuals who converted to persistent autoantibody positivity and two autoantibody-negative control groups (35 SOCs and 24 NECs) were typed for HLA-A class I alleles. The A1, A2 genotype was significantly increased among the autoantibody-positive subjects (47%) compared to autoantibody-negative SOCs (14%, P = 0.01) and NECs (13%, P = 0.02). Life-table analysis of DR3/4, DQB1*0302 siblings revealed a risk of 75% for development of islet autoantibodies by the age of 2 years for those with A1, A2. The HLA-A2 phenotype frequency was increased among an independent DR3/4, DQB1*0302 young diabetes cohort (64% versus 33% for autoantibody-negative NECs). These results suggest that a high incidence and early appearance of islet autoantibodies for siblings of patients with type 1A diabetes are associated with DR3/4, DQB1*0302 and potentially increased with HLA-A genotype A1, A2
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a HLA-A Antigens
|2 NLM
|
| 650 |
|
7 |
|a HLA-DQ Antigens
|2 NLM
|
| 650 |
|
7 |
|a HLA-DQ beta-Chains
|2 NLM
|
| 650 |
|
7 |
|a HLA-DQB1 antigen
|2 NLM
|
| 650 |
|
7 |
|a HLA-DR3 Antigen
|2 NLM
|
| 650 |
|
7 |
|a HLA-DR4 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class I
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 700 |
1 |
|
|a Eisenbarth, George S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Tianbao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Erlich, Henry A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bugawan, Teodorica L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Babu, Sunanda R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Barriga, Kathy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Norris, Jill M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hoffman, Michelle
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Klingensmith, Georgeanna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Liping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rewers, Marian
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a Diabetes Autoimmunity Study in the Young
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 102(2002), 3 vom: 22. März, Seite 217-24
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:102
|g year:2002
|g number:3
|g day:22
|g month:03
|g pages:217-24
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 102
|j 2002
|e 3
|b 22
|c 03
|h 217-24
|